Hepatic arterial infusion chemotherapy for post-operative liver metastases from pancreatic cancer in a patient with leukocytopenia: A case report

Ministry of Health, Labor and Welfare: The Dynamic Statistics of the Population in 2005. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei05/hyo7/htmluri.

Ishii H, Furuse J, Boku N, et al: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 40:573–579. 2010. View Article : Google Scholar : PubMed/NCBI

Evans DB, Abbruzzese JL and Willett CG: Cancer of the pancreas. Cancer: Priciples and Practice of Oncology. De Vita VT Jr, Hellman S and Rosenberg SA: 6th edition. Lippincott, Williams and Wilkins; Philadelphia: pp. 1126–1161. 2001

Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergo curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar

Aloia TE, Lee JE, Vauthey JN, et al: Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant chemotherapy? J Am Coll Surg. 204:347–355. 2007. View Article : Google Scholar : PubMed/NCBI

Sandy H, Bruckner H, Cooperman A, et al: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 89:314–327. 2000. View Article : Google Scholar

Ensminger WD, Rosowsky A and Raso V: A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluoroufacil. Cancer Res. 38:3789–3792. 1978.PubMed/NCBI

Vogl TJ, Schwarz W, Eichler K, et al: Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinoma and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 132:745–755. 2006. View Article : Google Scholar

Tse AN, Wu N, Patel D, et al: A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol. 64:935–944. 2009. View Article : Google Scholar : PubMed/NCBI

Van Riel JM, Peters GJ, Mammatas LH, et al: A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. Euro J Cancer. 45:2519–2527. 2009.PubMed/NCBI

Nagakawa T, Nagamori M, Futakami F, et al: Result of extensive surgery for pancreatic carcinoma. Cancer. 77:640–645. 1996. View Article : Google Scholar : PubMed/NCBI

Noto M, Miwa K, Kitagawa H, et al: Pancreas head carcinoma. Frequency of invasion to soft tissue adherent to the superior mesenteric artery. Am J Surg Pathol. 29:1056–1061. 2005.PubMed/NCBI

Traverso LW: Pancreatic cancer: surgery alone is not sufficient. Surg Endosc. 20(Suppl 2): 446–449. 2006. View Article : Google Scholar

Spitz FR, Abbruzzese JL, Lee JE, et al: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 15:928–937. 1997.PubMed/NCBI

Hoffman JP, Lipsitz S, Pisansky T, et al: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 16:317–323. 1998.

Palmer DH, Stocken DD, Hewitt H, et al: A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemicitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 14:2088–2096. 2007. View Article : Google Scholar

Golcher H, Brunner T, Grabenbauer G, et al: Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. EJSO. 34:756–764. 2008. View Article : Google Scholar : PubMed/NCBI

Turrini O, Viret F, Zabotto LM, et al: Neoadjuvant 5 fluorouracilcisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. Oncology. 76:413–419. 2009.PubMed/NCBI

Takai S, Satoi S, Yanagimoto H, et al: Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. Pancreas. 36:26–32. 2008. View Article : Google Scholar : PubMed/NCBI

Satoi S, Yanaagimoto H, Toyokawa H, et al: Surgical results after prepoerative chemoradiation therapy for patienes with pancreatic cancer. Pancreas. 38:282–288. 2009. View Article : Google Scholar : PubMed/NCBI

Cohen AD and Kemeny NE: An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist. 8:553–566. 2003. View Article : Google Scholar : PubMed/NCBI

Mocellin S, Pilati P, Lise M, et al: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 25:5649–5654. 2007. View Article : Google Scholar : PubMed/NCBI

Homma H, Akiyama T, Mezawa S, et al: Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy. Int J Clin Oncol. 9:197–201. 2004. View Article : Google Scholar : PubMed/NCBI

Miyanishi K, Ishiwatari H and Hayashi T: A phase I trial lf arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization. Jpn J Clin Oncol. 38:268–274. 2008. View Article : Google Scholar

Mogami K, Ichihara T, Sato T, et al: A case of the papilla lf vater accompanied witn a stricture of the celiac artery by the median arcuate ligament. Jpn J Gastroenterol Surg. 41:1588–1593. 2008. View Article : Google Scholar

Kikuchi K and Kanno H: Comparison for blood levels and clinical effects between tablet and other dosage forms of 5-fluorouracil (5-FU). Gan To Kagaku Ryouho. 6:559–565. 1979.

Maruyama S, Ando M and Watayo T: Concentration of 5-FU after hepatic artery infusion chemotherapy for liver metastases of colorectal cancer. Gan To Kagaku Ryouho. 30:1635–1638. 2003.PubMed/NCBI